A Study of Famitinib Plus Docetaxel in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)

NCT02364362 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer (NSCLC)

Interventions

DRUG: famitinib L + docetaxel
DRUG: famitinib M + docetaxel
DRUG: famitinib H + docetaxel

Sponsor

Jiangsu HengRui Medicine Co., Ltd.

Collaborators

[object Object]